상단영역

본문영역

  • 기자명 Jung Hyun Ko
  • Tech & Bio
  • Published 2020.09.10 02:31

[Pangyo Bio Issue] AZothBio and Autotelic Bio to conclude additional contract for joint development of immune anticancer drugs

On September 7, AZothBio (CEO Shin Jae-min)and Autotelic Bio (CEO Kim Tae-hoon) agreed to jointly develop an immuneanticancer drug. It is a follow-up contract signed about five months after thecontract for joint development of targeted cancer drugs in April.

The immune anticancer drug which they areto develop is not out on the market yet, and a few global companies areundergoing clinical trials. The two companies believe that they can implement afast follower strategy using AZothBio's AI platform and Autotelic Bio'sresearch know-how. This joint development project is a structure in which bothcompanies' technology and resources are jointly invested and equal rights aredivided. As a way to increase the work efficiency of the development ofanticancer drugs that the two companies are working on, a follow-up contractwas signed.

AZothBio is a company specializing in newdrug development AI platforms, and is working with new drug developmentcompanies by establishing an integrated platform that enables the data platformand AI model to operate efficiently. The project started with Autotelic Bio inApril, and they have completed the development of a target-specific selectionmodel (AI model) and is conducting research on the efficacy of new substances. Recently,they are discussing the expansion of their own AI new drug discovery platformto the platform of Rescale, a high-performance cloud computing company. Rescalehad also been selected as one of the Tech Against Covid program to support thefight against COVID-19, receiving free support of computing resources to builda library of small molecule-based COVID treatment drugs.

Autotelic Bio is a research and developmentcompany that focuses on the development of innovative anticancer drugs. It isdeveloping a variety of new immune and targeted anticancer drug pipelines, andits main research and development items are ATB-301, immune targetdouble-function anticancer drug, and ATB-310, target anticancer drug. FromOctober 2019 to February 2020, they attracted series A investment worth eightbillion won from Mega Investment, UTC Investment, Stone Bridge Ventures,Ajoupharm, and Korea Credit Guarantee Fund. Recently, they have recruited JeonYong-kwan, formerly the head of development division of Boryung Biopharma asthe clinical strategy development vice president, and Park Chang-hee, formerlythe synthetic drug development project leader at Hanmi Pharmaceutical ResearchLab as the Medicam Director.

하단영역